RNS Announcements

2023

Notice of AGM

ProBiotix Health plc (AQSE: PBX), a life sciences business developing probiotics to tackle cardiovascular disease and other lifestyle conditions, announces its audited results for the period ended 31 December 2023. 

Highlights

• Distribution agreement with Trans Chem for finished turnkey products in Australia and New Zealand
• Appointment of Niels Peter Bak as Technical Product Manager
• Launch of Cholbiome_CH a dual action bilayer tablet containing phytosterols and LP_LDL^® to increase opportunities in the US market
  

Post period end

• Appiontment of Michael Litichevski as Head of Global Sales
• Appointment of Mads Brandt as Global Supply Chain Director
• Partner agreement with SymbioPharm
  

Investor presentation

The Company will host a presentation for investors via the Investor Meet Company platform on Wednesday, 10 July at 11am BST. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9 July 2024 at 9am BST, or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet ProBiotix Health plc  via: https://www.investormeetcompany.com/probiotix-health-plc/register-investor

Investors who already follow ProBiotix Health plc on the Investor Meet Company platform will automatically be invited.

Steen Andersen, CEO of ProBiotix, commented: “We have continued to develop a business on becoming a solutions provider of finished probiotic products in consumer formats, both under our own brands and partner private labels, with the objective of building ProBiotix into a £10m turnover company in the years ahead.  We look to the future with enthusiasm and high confidence in building a valuable company for shareholders.”

For further information, please contact:

2022

Notice of AGM

ProBiotix Health plc (AQSE: PBX), a life sciences business developing probiotics to tackle cardiovascular disease and other lifestyle conditions, announces its audited results for the period ended 31 December 2023. 

Highlights

• Distribution agreement with Trans Chem for finished turnkey products in Australia and New Zealand
• Appointment of Niels Peter Bak as Technical Product Manager
• Launch of Cholbiome_CH a dual action bilayer tablet containing phytosterols and LP_LDL^® to increase opportunities in the US market
  

Post period end

• Appiontment of Michael Litichevski as Head of Global Sales
• Appointment of Mads Brandt as Global Supply Chain Director
• Partner agreement with SymbioPharm
  

Investor presentation

The Company will host a presentation for investors via the Investor Meet Company platform on Wednesday, 10 July at 11am BST. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9 July 2024 at 9am BST, or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet ProBiotix Health plc  via: https://www.investormeetcompany.com/probiotix-health-plc/register-investor

Investors who already follow ProBiotix Health plc on the Investor Meet Company platform will automatically be invited.

Steen Andersen, CEO of ProBiotix, commented: “We have continued to develop a business on becoming a solutions provider of finished probiotic products in consumer formats, both under our own brands and partner private labels, with the objective of building ProBiotix into a £10m turnover company in the years ahead.  We look to the future with enthusiasm and high confidence in building a valuable company for shareholders.”

For further information, please contact: